COMPOSITION FOR PRESERVING PLATELETS AND METHOD OF USING THE SAME

• US 20080233554A1
• Filed: 04/25/2008
• Published: 09/25/2008
• Est. Priority Date: 01/12/2005
• Status: Active Grant

• Current Assignee: Biovec Transfusion LLC
• Original Assignee: Biovec, LLC
• Inventors: Mousa, Shaker, Sehgal, Lakshman R.
• Granted Patent: US 8,129,103 B2
• Time in Patent Office: Days
• US Class Current: 435/2
• CPC Class Codes: A01N 1/02 Preservation of living parts
• CPC Class Codes: A01N 1/0215 Disinfecting agents, e.g. antimicrobials for preserving living parts
• CPC Class Codes: A01N 1/0226 Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients

Abstract

The present invention relates to compositions and methods for storing platelets to preserve the function and freshness of the platelets. More particularly, the present invention relates to the use of a preservative composition having an antiplatelet agent, an anticoagulant, and an oxygen carrier, for maintaining the freshness of platelets. Additionally, the composition may also contain an ultra-short acting broad spectrum anti-microbial agents. The preservative composition may be used to store platelets in a liquid state, a frozen state, or a freeze-dried state.

Claims

1. A method of extending the shelf-life of platelets, comprising the steps of:

(a) admixing a preservative composition with inactivated, functional platelets to provide a preserved platelet composition; and

(b) storing the preserved platelet composition in an oxygen-permeable container or an oxygen-impermeable container,

wherein the preservative composition comprises an antiplatelet agent, an anticoagulant, and an oxygen based carrier.

2. The method of claim 1, wherein said inactivated, functional platelets are substantially free of red blood cells and other blood nutrients.

3. The method of claim 1, wherein said antiplatelet agent is a compound that binds to or associates with GPIIb/IIIa sites.

4. The method of claim 1, wherein said oxygen carrier is a pharmaceutically acceptable oxygen carrier and is selected from the group consisting of hemoglobin, ferroprotoporphyrin, perfluorochemicals, and mixtures thereof.

5. The method of claim 4, wherein said oxygen carrier is a hemoglobin-based oxygen carrier.

6. A preserved platelet package, comprising:

the preserved platelet composition of claim 1, stored in an oxygen-permeable or in an oxygen-impermeable bag.

7. The method of claim 3, wherein said antiplatelet has a short to ultra-short half life.

8. The method of claim 7, wherein said antiplatelet has a circulating half-life of inhibition of about less than 4 hours.

9. The method of claim 1, wherein said antiplatelet agent is capable of reversibly blocking platelet activation and/or aggregation by blocking sites on the platelet surface.

10. The method of claim 1, wherein said antiplatelet agent is selected from the group consisting of DUP728, XJ757, XR299, eptifibatide, orbofiban, xemilofiban, Lamifiban, tirofiban (Aggrastat), and mixtures thereof.

11. The method of claim 1, wherein said antiplatelet agent is selected from the group consisting of linear and cyclic RGD analogs.

12. The method of claim 11, wherein said linear and cyclic RGD analogs are conjugated to a Nitric oxide donor.

13. The method of claim 1, wherein said antiplatelet agent comprises about 0.001 mg to about 5 mg of a GPIIb/IIIa inhibitor.

14. The method of claim 1, wherein said anticoagulant is a compound that reversibly inhibits factor Xa, or factor IIa, or both.

15. The method of claim 14, wherein said anticoagulant is a short-to-ultrashort acting Xa inhibitor with a circulating half-life of less than 4 hours.

16. The method of claim 15, wherein said anticoagulant is selected from the group consisting of DX-9065a, BX-80783 and RPR-120844.

17. The method of claim 14, wherein said anticoagulant is a short-to-ultrashort acting IIa inhibitor, and wherein said short-to-ultrashort acting IIa inhibitor is selected from the group consisting of hirudin, hirulog, melgatran, and combinations thereof.

18. The method of claim 9, wherein said anticoagulant is a combination of at least one short-to-ultrashort acting IIa inhibitor, and at least one short-to-ultrashort acting Xa inhibitor.

19. The method of claim 1, wherein said preservative composition further comprises a short-to-ultrashort acting broad spectrum anti-microbial agent.

20. The method of claim 19, wherein said short-to-ultrashort acting anti-microbial agent is selected from the group consisting of:

Penicillin, Natural penicillins, Semisynthetic penicillins, Monobactam, Cephalosporin Carbapenems Vancomycin, Isoniazid (INH), Ethambutol, Aminoglycoside, Tetracycline, Chloramphenicol, Macrolide, Rifamycin, Quinolone, Fluoroquinolone, Sulfonamide, Synergism, Polyene antibiotic, Imidazole, Triazole, Griseofulvin and combinations thereof.